La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
AVITA Medical Croissance future
Future contrôle des critères 5/6
AVITA Medical is forecast to grow earnings and revenue by 69.9% and 26.5% per annum respectively. EPS is expected to grow by 68.2% per annum. Return on equity is forecast to be -34.2% in 3 years.
Informations clés
69.9%
Taux de croissance des bénéfices
68.2%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 30.4% |
| Taux de croissance des recettes | 26.5% |
| Rendement futur des capitaux propres | -34.2% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 12 Aug 2024 |
Mises à jour récentes de la croissance future
Recent updates
AVITA Medical, Inc. (NASDAQ:RCEL) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 11
AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Jul 18Is AVITA Medical (NASDAQ:RCEL) A Risky Investment?
Jun 18Little Excitement Around AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues As Shares Take 39% Pounding
Apr 12AVITA Medical, Inc.'s (NASDAQ:RCEL) Price Is Right But Growth Is Lacking After Shares Rocket 39%
Feb 02The Market Doesn't Like What It Sees From AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues Yet As Shares Tumble 32%
Oct 20Avita Medical appoints James Corbett as CEO
Sep 29AVITA Medical says trial evaluating its RECELL system to treat vitiligo met main goal
Sep 12Avita's burn therapy Recell gets insurance coverage in Japan following approval
Sep 01AVITA Medical GAAP EPS of -$0.25 beats by $0.15, revenue of $8.34M beats by $1.18M
Aug 11AVITA Medical Is Interesting, But Not Just Yet
Dec 21AVITA Medical reports preliminary Q2 revenue in-line with consensus
Jan 12AVITA: COVID-19's Impact
Nov 17Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 136 | 0 | 8 | 10 | 8 |
| 12/31/2025 | 102 | -26 | -21 | -19 | 10 |
| 12/31/2024 | 69 | -53 | -46 | -42 | 11 |
| 6/30/2024 | 54 | -50 | -58 | -53 | N/A |
| 3/31/2024 | 51 | -45 | -52 | -50 | N/A |
| 12/31/2023 | 50 | -35 | -39 | -38 | N/A |
| 9/30/2023 | 45 | -34 | -32 | -31 | N/A |
| 6/30/2023 | 41 | -31 | -25 | -24 | N/A |
| 3/31/2023 | 37 | -26 | -20 | -19 | N/A |
| 12/31/2022 | 34 | -27 | -20 | -19 | N/A |
| 9/30/2022 | 32 | -30 | -21 | -21 | N/A |
| 6/30/2022 | 30 | -30 | -19 | -18 | N/A |
| 3/31/2022 | 32 | -29 | -19 | -19 | N/A |
| 12/31/2021 | 33 | -25 | -19 | -18 | N/A |
| 9/30/2021 | 31 | -22 | -20 | -19 | N/A |
| 6/30/2021 | 29 | -27 | -27 | -26 | N/A |
| 3/31/2021 | 23 | -35 | -29 | -28 | N/A |
| 12/31/2020 | 18 | -44 | -28 | -27 | N/A |
| 9/30/2020 | 16 | -49 | -27 | -26 | N/A |
| 6/30/2020 | 14 | -42 | -24 | -23 | N/A |
| 3/31/2020 | 12 | -36 | -24 | -23 | N/A |
| 12/31/2019 | 11 | -28 | -22 | -21 | N/A |
| 9/30/2019 | 8 | -23 | -22 | -21 | N/A |
| 6/30/2019 | 5 | -25 | -20 | -19 | N/A |
| 3/31/2019 | 4 | -22 | -19 | -18 | N/A |
| 12/31/2018 | 2 | -18 | -14 | -13 | N/A |
| 9/30/2018 | 1 | -15 | -13 | -13 | N/A |
| 6/30/2018 | 1 | -13 | -13 | -13 | N/A |
| 3/31/2018 | 1 | -12 | N/A | -11 | N/A |
| 12/31/2017 | 1 | -11 | N/A | -9 | N/A |
| 9/30/2017 | 1 | -10 | N/A | -8 | N/A |
| 6/30/2017 | 1 | -9 | N/A | -7 | N/A |
| 3/31/2017 | 1 | -8 | N/A | -6 | N/A |
| 12/31/2016 | 1 | -7 | N/A | -6 | N/A |
| 9/30/2016 | 1 | -8 | N/A | -6 | N/A |
| 6/30/2016 | 1 | -8 | N/A | -6 | N/A |
| 3/31/2016 | 1 | -8 | N/A | -7 | N/A |
| 12/31/2015 | 1 | -7 | N/A | -7 | N/A |
| 9/30/2015 | 1 | -6 | N/A | -5 | N/A |
| 6/30/2015 | 1 | -6 | N/A | -5 | N/A |
| 3/31/2015 | 1 | -5 | N/A | -4 | N/A |
| 12/31/2014 | 1 | -5 | N/A | -4 | N/A |
| 9/30/2014 | 2 | -5 | N/A | -5 | N/A |
| 6/30/2014 | 3 | -5 | N/A | -7 | N/A |
| 3/31/2014 | 3 | -6 | N/A | -7 | N/A |
| 12/31/2013 | 3 | -7 | N/A | -7 | N/A |
| 9/30/2013 | 3 | -7 | N/A | -7 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: RCEL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Bénéfices vs marché: RCEL is forecast to become profitable over the next 3 years, which is considered above average market growth.
Croissance élevée des bénéfices: RCEL is expected to become profitable in the next 3 years.
Chiffre d'affaires vs marché: RCEL's revenue (26.5% per year) is forecast to grow faster than the US market (8.8% per year).
Croissance élevée des revenus: RCEL's revenue (26.5% per year) is forecast to grow faster than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: RCEL is forecast to be unprofitable in 3 years.